Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Cash-to-Debt

: 0.30 (As of Dec. 2023)

View and export this data going back to 1952. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bristol-Myers Squibb Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.30.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Bristol-Myers Squibb Co couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Bristol-Myers Squibb Co's Cash-to-Debt or its related term are showing as below:

BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.23 Med: 0.51 Max: 1.19
Current: 0.3

During the past 13 years, Bristol-Myers Squibb Co's highest Cash to Debt Ratio was 1.19. The lowest was 0.23. And the median was 0.51.

BMY's Cash-to-Debt is ranked worse than
69.08% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs BMY: 0.30

Bristol-Myers Squibb Co Cash-to-Debt Historical Data

The historical data trend for Bristol-Myers Squibb Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.32

0.38

0.23

0.30

Bristol-Myers Squibb Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																0.23	0.24	0.22	0.20	0.30

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bristol-Myers Squibb Co Cash-to-Debt Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Cash-to-Debt falls into.

Bristol-Myers Squibb Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Bristol-Myers Squibb Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12280	/	(3281	+	38183)
	=	0.30

Bristol-Myers Squibb Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12280	/	(3281	+	38183)
	=	0.30

Bristol-Myers Squibb Co (NYSE:BMY) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Bristol-Myers Squibb Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (Bristol-Myers Squibb Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

430 East 29th Street, 14th Floor, New York, NY, USA, 10016

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Executives

Christopher S. Boerner	officer: EVP, Chief Commercial Officer	21823 30TH DRIVE S, BOTHELL WA 98021
Samuels Theodore R. Ii	director	1990 E. GRAND AVE., EL SEGUNDO CA 90245
Cari Gallman	officer: EVP, Corporate Affairs	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Ann Powell Judge	officer: SVP, Human Resources	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Robert M Plenge	officer: EVP, Chief Research Officer	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Rupert Vessey	officer: Pres., Research & Early Dev.	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Adam Lenkowsky	officer: EVP, Chief Commercial Officer	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Giovanni Caforio	officer: EVP & Chief Commercial Officer	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
David V Elkins	officer: EVP, Chief Financial Officer	C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417
Deepak Bhatt	director	BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016
Sandra Leung	officer: Vice President and Secretary	C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164
Sharon Greenlees	officer: SVP & Controller	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Karin Shanahan	officer: EVP, Glob. Prod. Dev. & Supply	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Gregory Scott Meyers	officer: EVP, Chief Digital & Tech Off.	BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Autenried Paul Von	officer: SVP, Enterp. Services & CIO	BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543